1. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17.

2. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20:1897-909.

3. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868-76.

4. Qazi S, Uckun FM. Wilms’ tumor gene (WT1) expression in cytogenetically distinct subsets of AML. Available from: [Last accessed on 7 Nov 2018].

5. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, et al. WT1 mutations in T-ALL. Blood 2009;114:1038-45.

6. Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007;25:3739-45.

7. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24:1507-15.

8. Busse A, Gökbuget N, Siehl JM, Hoelzer D, Schwartz S, et al. Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 2009;88:1199-205.

9. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adultacute T-lymphoblastic leukemia. Haematologica 2010;95:942-9.

10. Chiusa L, Francia di Celle P, Campisi P, Ceretto C, et al. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica 2006;91:270-1.

11. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms’ tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:1360-7.

12. Xu B, Song X, Yip NC, Xiao P, Zhang Y, et al. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology 2010;15:74-80.

13. Boublikova L, Kalinova M, Ryan J, Quinn F, O’Marcaigh A, et al. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006;20:254-63.

14. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-7.

15. Ujj Z, Buglyó G, Udvardy M, Vargha G, Biró S, et al. WT1 overexpression affecting clinical outcome in non-hodgkin lymphomas and adult acute lymphoblastic leukemia. Pathol Oncol Res 2014;20:565-70.

16. Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U. WT1 gene expression in childhood leukemias. Acta Haematol 1999;102:72-6.

17. Ayatollahi H, Sadeghian MH, Naderi M, Jafarian AH, Shams SF, et al. Quantitative assessment of Wilms tumor 1 expression by realtime quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. J Res Med Sci 2017;22:54.

18. Niavarani A, Herold T, Reyal Y, Sauerland MC, Buchner T, et al. A 4-gene expression score associated with high levels of Wilms tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia. Br J Haematol 2016;172:401-11.

19. Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, et al. Induction of immune response after allogeneic Wilms’ tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and post-transplantation relapse. Biol Blood Marrow Transplant 2016;22:2149-54.

20. Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, et al. A randomized phase II trial of adjuvant Galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res 2017;23:7483-9.

21. Dao T, Yan S, Veomett N, Pankov D, Zhou L, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5:176ra33.

22. Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia 2017;31:1788-97.

23. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116:171-9.

24. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 2017;130:1985-94.

25. Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, et al. A novel DNA vaccine platform enhances neo-antigen-like T cell responses against WT1 to break tolerance and induce anti-tumor immunity. Mol Ther 2017;25:976-88.

26. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015;33:1079-86.

27. Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, et al. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology 2016;6:e1252895.

28. Uckun FM, Myers DE, Qazi S, Ozer Z, Rose R, et al. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. J Clin Invest 2015;125:1006-18.

29. Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, et al. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood 2013;121:4348-54.

30. Uckun FM, Ma H, Cheng J, Myers DE, Qazi S. CD22ΔE12 as a molecular target for RNAi therapy. Br J Haematol 2015;169:401-14.

31. Uckun FM, Ma H, Ishkhanian R, Arellano M, Shahidzadeh A, et al. Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS One 2013;8:e80732.

32. Bengtsson H, Simpson K, Bullard J, Hansen K. Aroma.affymetrix: a generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. Tech Report #745. Department of Statistics, University of California, Berkeley, 2008.

33. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125-34.

34. van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122:2622-9.

35. Liu WM, Li R, Sun JZ, Wang J, Tsai J, et al. PQN and DQN: algorithms for expression microarrays. J Theor Biol 2006;243:273-8.

36. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010;28:2529-37.

37. Bordin F, Piovan E, Masiero E, Ambesi-Impiombato A, Minuzzo S, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica 2018;103:266-77.

38. Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8:e53190.

39. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007;110:1924-32.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us


All published articles will preserved here permanently:


All published articles will preserved here permanently: